Advertisement
Canada markets close in 9 minutes

  • S&P/TSX

    21,706.02
    +49.97 (+0.23%)
     

  • S&P 500

    5,021.55
    -0.66 (-0.01%)
     

  • DOW

    37,851.29
    +97.98 (+0.26%)
     

  • CAD/USD

    0.7265
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    82.68
    -0.01 (-0.01%)
     

  • Bitcoin CAD

    87,153.37
    +2,919.98 (+3.47%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,395.40
    +7.00 (+0.29%)
     

  • RUSSELL 2000

    1,948.45
    +0.50 (+0.03%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • NASDAQ

    15,638.62
    -44.75 (-0.29%)
     

  • VOLATILITY

    17.92
    -0.29 (-1.59%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • CAD/EUR

    0.6821
    +0.0019 (+0.28%)
     
MARKETS LIVE BLOG:

STOCKS WOBBLE WITH NETFLIX EARNINGS ON DECK

Gas prices: Why one U.S. region will see 'stiff increases' this week

Valeant to report first-quarter results on June 7

Reuters
The headquarters of Valeant Pharmaceuticals International Inc., seen in Laval, Quebec November 9 2015. REUTERS/Christinne Muschi (Reuters)

(Reuters) - Valeant Pharmaceuticals Inc <VRX.TO> <VRX.N>, which has come under scrutiny for its business and accounting practices, said on Tuesday it would host a conference call on June 7 to discuss first-quarter results.

The Beleaguered Canadian drugmaker reiterated that it expects to file its quarterly report with U.S. and Canadian regulators on or before June 10, ahead of a July 31 deadline.

The troubled drugmaker filed its 2015 financial report in late April, allaying concerns about a possible default on its debt of more than $30 billion.

The company missed an original March 15 deadline, citing an in-house review of its accounting practices. The probe found problems dating back to 2014.

(Reporting by Arathy S Nair in Bengaluru)